get a key
steadybase-$ company RNAZ
account_id none on file
legal_name Transcode Therapeutics, Inc.
ticker RNAZ
cik 1829635
domain transcodetherapeutics.com
entry_point_account_id none on file
name TransCode Therapeutics Inc.
exchange Nasdaq
sector Health Care
calls 0 filings 4 executives 0 family 0
why_nownone on file
callsnone on file
filings
John Tattory was appointed to serve as the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, effective as of September 9, 2026.

filing / Sep 11, 2026 / receipt

If we fail to raise capital or enter into such agreements as and when needed, we will likely need to consider cost reduction strategies, which may include, among others, amending, delaying, limiting, reducing, or terminating our development programs, and we may need to seek an in-court or out-of-court restructuring of our liabilities.

filing / Aug 14, 2026 / receipt

If we are unable to raise additional funds when needed, we will likely need to consider cost reduction strategies which may include, among others, amending, delaying, limiting, reducing, or terminating our development programs, and we may need to seek an in-court or out-of-court restructuring of our liabilities.

filing / Aug 14, 2026 / receipt

From February 1, 2023, to January 31, 2025, the Company subleased 4,837 square feet of laboratory and office space in Newton, Massachusetts, which it accounted for in accordance with to ASU 842.

filing / Aug 14, 2026 / receipt

executivesnone on file
familynone on file
upcoming
2026-11-13 earnings call scheduled ir
changes
2025-10-08 Interim Chief Executive Officer, departed sec_8k
mcp_package_hint
steadybase-$